A novel tumor-activated ALA fusion protein for specific inhibition on the growth and invasion of breast cancer cells MDA-MB-231-Reference-Cited by-同舟云学术

A novel tumor-activated ALA fusion protein for specific inhibition on the growth and invasion of breast cancer cells MDA-MB-231

Published:2017-01-01 Issue:1 Volume:24 Page:1811-1817
ISSN:1071-7544
Container-title:Drug Delivery
language:en
Short-container-title:Drug Delivery

Author:

Liu Xiufeng¹²,Liu Xintong³,Sunchen Suwen¹,Liu Meixia¹,Shen Chen¹,Wu Juanjuan¹,Zhao Wanli¹,Yu Boyang¹²,Liu Jihua¹²

Affiliation:

1. State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China;

2. Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Biotechnology of TCM, China Pharmaceutical University, Nanjing, PR China;

3. School of Life Science and Technology, China Pharmaceutical University, Nanjing, PR China

Funder

Natural Science Foundation of Jiangsu Province

Fundamental Research Funds for the Central

College Students Innovation Project

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,General Medicine

Link

https://tandfonline.com/doi/pdf/10.1080/10717544.2017.1406560

Reference30 articles.

1. Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release

2. Therapeutic Peptides and Proteins

3. Bruno BJ, Miller GD, Lim CS. (2013). Basics and recent advances in peptide and protein drug delivery.

4. Scorpion venoms as a potential source of novel cancer therapeutic compounds

5. Drug Carriers for the Delivery of Therapeutic Peptides

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. uPAR, beyond regulating physiological functions, has orchestrated roles in cancer (Review);International Journal of Oncology;2022-10-18

2. The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities;Cancers;2021-10-27

3. Recent developments in animal venom peptide nanotherapeutics with improved selectivity for cancer cells;Biotechnology Advances;2021-09

4. Protease-triggered bioresponsive drug delivery for the targeted theranostics of malignancy;Acta Pharmaceutica Sinica B;2021-08

5. Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions;Biotechnology Advances;2021-03